CYP2D6 and CYP2C19 genotypes of patients with terodilin cardiotoxicity identified through the yellow card system

British Journal of Clinical Pharmacology

Volumn 50, Issue 1, 2000, Pages 77-80

  Ford, Gary A ^a,b   Wood, Susan M ^b   Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

CYP2C19; CYP2D6; Pharmacovigilance; Terodiline

Indexed keywords

CYTOCHROME P450 2C19; DEBRISOQUINE 4 HYDROXYLASE; TERODILINE;

AGED; ALLELE; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GENOTYPE; HEART VENTRICLE TACHYCARDIA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TORSADE DES POINTES;

AGED; AGED, 80 AND OVER; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BUTYLAMINES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; DNA; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HEART; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PARASYMPATHOLYTICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; TACHYCARDIA, VENTRICULAR; TORSADES DE POINTES;

EID: 0034083503     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00230.x     Document Type: Article

References (16)

1. 1 Stewart DA, Taylor J, Ghosh GJA, et al. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 1992; 42: 577-580.
2. 2 Connolly MJ, Astridge PS, White EG, Morley CA, Campbell Cowan J. Torsades de pointes ventricular tachycardia and terodiline. Lancet 1991; 338: 344-345.
3. 3 Thomas SHL, Higham PD, Kamali F, Woods P, Campbell R, Ford GA. Electrocardiographic effects and plasma concentrations of terodiline enantiomers in patients with urinary incontinence. Br Heart J 1995; 74: 53-56.
4. 4 Lindeke B, Ericsson O, Jonsson A, Noren B, Stromberg S, Vangbo B. Biotransformation of terodiline. III Opposed stereoselectivity in the benzylic and aromatic hydroxylations of rat liver microsomes. Xenobiotica 1987; 17: 1269-1278.
5. 5 Noren B, Stromberg S, Erricsson O, Lindeke B. Biotransformation of terodiline. V Stereoselectivity in hydroxylation by human liver microsomes. Chem Biol Interact 1989; 71: 325-337.
6. 6 Hallen B, Gabrielsson J, Nyambati S, Johansson A, Larsson E, Guilbaud O. Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites. Pharmacol Toxicol 1995; 76: 171-177.
7. 7 Buffone GJ, Darlington GJ. Isolation of DNA from biological specimens without extraction with phenol. Clin Chem 1985; 31: 164-165.
8. 8 Daly AK, Steen VM. Fairbrother KS, Idle JR CYP2D6 multiallelism. Meth Enzymol 1996; 272: 199-210.
9. 9 de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-15422.
10. 10 de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S) -mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
11. 11 Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. The genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (P450IID6) phenotypes. Pharmacogenetics 1991; 1: 33-41.
12. 12 Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheumatic Diseases 1996; 55: 66-68.
13. 13 Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 59-64.
14. 14 Hartigan-Go K, Bateman DN, Daly AK, Thomas SHL. Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther 1996; 60: 89-98.
15. 15 Edeki TI, Goldstein JA, de Morais SMF, et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 1996; 6: 357-360.
16. 16 Ibeanu GC, Blaisdell J, Ghanayem BI, et al. An additional defective allele, CYP2C19*5, contributes to the M-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8: 129-135.